DELRAY BEACH, Fla., Oct. 8, 2024 /PRNewswire/ -- The peripheral vascular devices market is set to grow significantly, reaching an estimated USD 14.73 billion by 2029 from USD 11.43 billion in 2024, with a compound annual growth rate (CAGR) of 5.2%. This growth is driven by the rising incidence of peripheral artery disease (PAD) linked to an aging population and increasing rates of diabetes, hypertension, and obesity. Key advancements in technology, including minimally invasive procedures and drug-eluting stents, are enhancing patient outcomes and driving demand. However, challenges such as product recalls and a complex regulatory landscape pose risks to market expansion. North America leads the market, fueled by robust healthcare infrastructure and high cardiovascular disease prevalence, while emerging markets present lucrative opportunities due to increasing healthcare investments. Major players like Boston Scientific, Medtronic, and Abbott are shaping the industry's future with continuous innovations and strategic partnerships.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=790
Browse in-depth TOC on "Peripheral Vascular Devices Market"
365 - Tables
52 - Figures
323 - Pages
Based on type, the Peripheral vascular devices Market is segmented into Angioplasty balloons, Angioplasty stents, Catheters, Endovascular aneurysm repair stent grafts, Inferior cava filters, Plaque modification devices, Hemodynamic flow alteration devices, and Other peripheral vascular devices. Peripheral vascular devices markets are dominated by angioplasty stents and relate to the high prevalence of peripheral artery disease, often seen in millions worldwide, where it causes narrowing or blockage in the peripheral arteries, especially the legs. "Stents are used in combination with balloon angioplasty to help restore blood flow by propping open narrowed arteries from plaque buildup," according to End. Their ability to maintain the arteries open and prevent re-stenosis of the arterial lumen following the placement of a stent has made them one of the most sought-after treatments for PAD, increasing the growing demand in the peripheral vascular market.
Drug-eluting stents have further solidified the primary position of angioplasty stents on the market. The Eluvia Drug-Eluting Vascular Stent, like other drug-eluting stents, release medication that stops the overgrowth of tissue within the artery, ensuring that the arteries do not once again close off. This would imply better long-term results than the traditional stents for the patients, hence making these more appealing to the healthcare providers. In addition to this, stents also offer a minimally invasive treatment mode that is essential to shorter recovery times for the patients, lower procedural risks than open surgery and another reason for its broad acceptance in clinical practice.
Angioplasty stents are flexible and can be used in a variety of vascular conditions, such as CLI and renal artery stenosis; they are truly an all-around solution for peripheral vascular interventions. Additionally, their ability to improve patient outcomes while undergoing constant innovations, such as bioabsorbable stents, positions them strongly in the market for peripheral vascular devices. The aged population is increasing, especially in developed countries; this increases the demand for these devices because they are used in treating vascular disease conditions associated with aging, which ensures continued market leadership position.
Based on geography, The Peripheral vascular devices Market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounts for the largest share during the forecast period. North America, notably the United States and Canada, has a sophisticated healthcare infrastructure, including well-established hospital systems, healthcare facilities, and broad networks of healthcare providers. The aging population, sedentary lifestyles, and dietary habits all contribute to the increased prevalence of peripheral vascular diseases thereby increasing the demand for peripheral vascular devices.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=790
The Peripheral Vascular devices market is fragmented. A few strong players in this market are Boston Scientific Corporation (U.S.), Medtronic (U.S), Philips (Japan), Merit Medical Systems (U.S.), Abbott (U.S.), and Terumo Corporation (Japan) among others.
BOSTON SCIENTIFIC CORPRATION (U.S):
Boston Scientific Corporation is the world's leader in developing, manufacturing, and marketing medical devices for a variety of health sciences. Those include peripheral vascular interventions and interventional cardiology, along with endoscopy and many others. Under the peripheral vascular devices section, the company provides a wide portfolio of pioneering products that are designed to treat diseases of the vascular system. These include drug-eluting stents, atherectomy systems, embolic protection devices, guidewires, catheters, and balloon dilation devices. Peripheral vascular applications of their well-known products include Eluvia Drug-Eluting Vascular Stent System, ROTAPRO Rotational Atherectomy System, AngioJet Thrombectomy System, and Mustang PTA Balloon Catheter. It applies to these complex cases diagnosed for PAD, CLI, and several vascular diseases involving arteries and veins except for the heart and brain.
Boston Scientific continues to build its portfolio through acquisitions that strengthen its presence in vascular devices. Peripheral vascular has among its subsidiaries key contributors, like BTG International-an interventional medicine company focused on vascular diseases and cancer-and Claret Medical with its embolic protection device Sentinel Cerebral Protection System. It should also be noted that Baylis Medical, specialized in advanced cardiology and vascular instruments, was acquired by Boston Scientific Corporation to further build up its interventional suite. Acquisitions give Boston Scientific the ability to provide comprehensive solutions by aiding physicians in the treatment of the entire continuum of vascular conditions.
Terumo Corporation (Japan):
Terumo Corporation is a Tokyo, Japan-based company, especially named for its excellence in the concepts of cardiovascular and vascular care. Peripheral vascular devices, as part of their extensive offerings, emphasize the treatment of PAD (peripheral artery disease), DVT (deep vein thrombosis), and other arterial and venous conditions outside the heart and brain. Products include minimally invasive technologies to advanced therapeutic systems, aiding physicians in efforts to improve patient outcomes while minimizing complications of vascular diseases. Some of the products offered by Terumo Corporation in the peripheral vascular devTerumo's subsidiaries have complemented the company's strong push in the global peripheral vascular market. Of the most important of these, Terumo Interventional Systems (TIS) is actively developing technologies for vascular access, embolization, and peripheral vascular interventions. MicroVention, Inc., another Terumo subsidiary, is primarily engaged in neurovascular interventions, though they have products complementary to Terumo's vascular portfolio, especially in embolization and microcatheter technologies. In addition, Terumo Medical Corporation is responsible for the development and distribution of Terumo's interventional products in key markets and supports the further growth of the company's business in the global peripheral vascular market.
Medtronic (U.S):
Medtronic is one of the world's largest medical technology companies, renowned for its innovative medical devices and therapies across various healthcare sectors, including cardiovascular, neurosurgery, diabetes, and vascular interventions. In the peripheral vascular devices market, Medtronic plays a pivotal role by offering a wide range of products designed to treat peripheral artery disease (PAD), deep vein thrombosis (DVT), and other conditions affecting the peripheral vasculature. Medtronic's cutting-edge devices assist healthcare professionals in restoring blood flow and improving patient outcomes in cases involving narrowed or blocked arteries outside the heart and brain. The company offers IN.PACT Admiral drug-coated balloon, vascular stents, Atherectomy systems, and Endovascular aneurysm repair stents among others.
Medtronic's leadership in the peripheral vascular market is further enhanced by its subsidiaries and strategic acquisitions. Covidien, a major acquisition, has significantly bolstered Medtronic's portfolio in the vascular space. Covidien brought products such as ClosureFast and Venaseal, which are used for treating chronic venous insufficiency. Additionally, Aptus Endosystems, which specializes in endovascular aneurysm repair technologies, complements Medtronic's offerings with its Heli-FX EndoAnchor System. Another critical acquisition is Ardian, which focuses on renal denervation, contributing to Medtronic's advanced therapeutic solutions for vascular conditions
For more information, Inquire Now!
Related Reports:
Sleep Apnea Devices Market
Cardiac Rhythm Management Devices Market
Patient Monitoring Devices Market
Spinal Implants Market
Respiratory Care Devices Market
Get access to the latest updates on Peripheral Vascular Devices Companies and Peripheral Vascular Devices Market Share
About MarketsandMarkets:
MarketsandMarkets has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/peripheral-vascular-devices-market-to-hit-usd-14-73-billion-by-2029-with-5-2-cagr--marketsandmarkets-302269735.html
